Erratum: Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity (Leukemia (2013) 27 (2200-2208) DOI: 10.1038/leu.2013.169);Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

Leukemia

Volumn 27, Issue 11, 2013, Pages 2200-2208

  Horl S ^a   Banki Z ^a   Huber, G ^a   Ejaz, A ^a   Windisch, D ^a   Muellauer, B ^a   Willenbacher, E ^a   Steurer, M ^a   Stoiber, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

chronic lymphocytic leukemia; complement factor H; complement dependent cytotoxicity; rituximab

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; RITUXIMAB;

ARTICLE; ASSAY; CANCER CELL; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 84887321596     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.230     Document Type: Erratum

References (49)

1. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13: 954-966.
2. Cartron G, Trappe RU, Solal-Ce? ligny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011; 17: 19-30.
3. Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia 2010; 24: 500-511.
4. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010; 28: 1863-1869.
5. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
6. Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008; 45: 95-103. (Pubitemid 351434408)
7. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642. (Pubitemid 39434941)
8. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70: 3209-3217.
9. Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res 2009; 15: 3624-3632.
10. Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011; 96: 1822-1830.
11. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587. (Pubitemid 36900094)
12. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471. (Pubitemid 46594097)
13. Stoiber H, Clivio A, Dierich MP. Role of complement in HIV infection. Annu Rev Immunol 1997; 15: 649-674. (Pubitemid 27169295)
14. Durrant LG, Spendlove I. Immunization against tumor cell surface complementregulatory proteins. Curr Opin Invest Drugs 2001; 2: 959-966. (Pubitemid 32700340)
15. Hu W, Ge X, You T, Xu T, Zhang J, Wu G et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 2011; 71: 2298-2307.
16. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009; 30: 286-292.
17. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98: 1352-1357.
18. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
19. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999; 20: 576-582.
20. Haeney MR. The role of the complement cascade in sepsis. J Antimicrob Chemother 1998; 41(Suppl A): 41-46. (Pubitemid 28062143)
21. Rodrguez de Co? rdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sa?nchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355-367. (Pubitemid 38639887)
22. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000; 164: 6075-6081. (Pubitemid 30389858)
23. Gasque P, Julen N, Ischenko AM, Picot C, Mauger C, Chauzy C et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992; 149: 1381-1387.
24. Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bj?ge L, Bu?tzow R et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002; 87: 1119-1127. (Pubitemid 35418107)
25. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000; 275: 16666-16672. (Pubitemid 30398895)
26. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 2007; 178: 5991-5998. (Pubitemid 46674397)
27. Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat 2006; 27: 21-30. (Pubitemid 43042963)
28. Schmidt CQ, Herbert AP, Hocking HG, Uhrn D, Barlow PN. Translational minireview series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol 2008; 151: 14-24. (Pubitemid 350231000)
29. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol 2008; 181: 2610-2619.
30. Oppermann M, Manuelian T, Jo? zsi M, Brandt E, Jokiranta TS, Heinen S et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006; 144: 342-352.
31. Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 2006; 177: 6308-6316. (Pubitemid 44628849)
32. Herbert AP, Uhrn D, Lyon M, Pangburn MK, Barlow PN. Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure. J Biol Chem 2006; 281: 16512-16520.
33. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF, Ward HM et al. Identification of the second heparin-binding domain in human complement factor H. J Immunol 1998; 160: 3342-3348. (Pubitemid 28164726)
34. Perkins SJ, Nan R, Okemefuna AI, Li K, Khan S, Miller A. Multiple interactions of complement Factor H with its ligands in solution: a progress report. Adv Exp Med Biol 2010; 703: 25-47.
35. Bellosillo B, Villamor N, Lo? pez-Guillermo A, Marce? S, Esteve J, Campo E et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98: 2771-2777.
36. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12: 4027-4035. (Pubitemid 44078090)
37. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908. (Pubitemid 30412866)
38. Harjunpa?a? A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634-641. (Pubitemid 30353375)
39. Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K et al. Depletion of functionally active CD20\+ T cells by rituximab treatment. Arthritis Rheum 2009; 60: 3563-3571.
40. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006; 91: 176-183.
41. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol Apr 47: 107-114.
42. Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008; 32: 1849-1856.
43. Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008; 101: 737-740.
44. Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ et al. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer 2011; 128: 2192-2201.
45. Giddings KS, Zhao J, Sims PJ, Tweten RK. Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. Nat Struct Mol Biol 2004; 11: 1173-1178.
46. Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol 2012; 87: 880-885.
47. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010; 42: 772-776.
48. Jak M, van Bochove GG, van Lier RA, Eldering E, van Oers MH. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. Leukemia 2011; 25: 968-978.
49. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003; 17: 900-909. (Pubitemid 36626318)